A germline variant of ring finger protein 43 in an early onset, treatment-resistant metastatic gastric cancer: a case report
- PMID: 40950348
- PMCID: PMC12432919
- DOI: 10.21037/jgo-2025-77
A germline variant of ring finger protein 43 in an early onset, treatment-resistant metastatic gastric cancer: a case report
Abstract
Background: Ring finger protein 43 (RNF43) is an E3 ubiquitin-protein ligase that functions as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis, and subsequent degradation of Frizzled receptors within the Wnt receptor complex. It exerts its effects on both canonical and non-canonical Wnt signaling pathways.
Case description: This case report describes a 49-year-old female patient with a significant family history of cancer and parental consanguinity who was diagnosed with treatment-resistant stage IV gastric adenocarcinoma. Genomic profiling conducted via liquid biopsy identified a missense variant in RNF43 exon 9 (NM_017763.6, c.1948C>T; Arg650Ter) with a high variant allele frequency (VAF) of 49.5%. Confirmation of the R650* variant at the germline level underscores its clinical significance in early onset gastric cancer (GC) pathogenesis.
Conclusions: While interpretations of its pathogenicity vary in the ClinVar database, the application of the American College of Medical Genetics (ACMG) criteria suggests its potential involvement in cancer pathogenesis. This report highlights the necessity for further research to elucidate the role and impact of RNF43 in GC progression and develop specific preventive measures for affected families as genetic testing and counseling in high-risk families.
Keywords: Ring finger protein 43 (RNF43); case report; early-onset; gastric cancer (GC); germline variant.
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2025-77/coif). I.N.R. reports FONDECYT grant (No. 11220563) from Chilean Government. M.G. reports receiving FONDECYT grant (No. 1221499) from Chilean Goverment; serving as Principal Investigator in clinical trials of MSD, BMS, Novartis, Roche, Astellas, Deciphera, PPD, IQVIA, Bayer, Principia, Covance, Daiichi-Sankyo, Basilea, PRA-Exelisis, Syneos, Zimeworks; serving on Scientific Advisory Board for Bayer, Novartis, MSD, BMS, Pfizer, Macrogenic, Merck; Teaching/Speaker Bureau Activities in Novartis, Pfizer, Bayer, BMS,MSD, GBT Biotoscana, Lilly; serving as Member of Societies and collaborative groups: ASCO, ESMO, ENETS, IGCS, SLAGO, SCOM, GOCCHI, Horizon 2020, GCCG and PanCancer; and President of GLOD. Grupo Latinoamericano de Oncología Digestiva. The other authors have no conflicts of interest to declare.
Figures


References
-
- Departamento de Epidemiologia. Ministerio de Salud (2024). Informe de Mortalidad por Cáncer en Chile. Periodo 2009-2020.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous